Article List

WPRIM Management System> DCMS> Kidney Research and Clinical Practice> 2013> 32> 1

Volume: 32 Issue: 1

1. Sulodexide in IgA nephropathy.	Page:47—48
2. Association of acute tubular necrosis with gross hematuria in cirrhosis-related immunoglobulin A nephropathy.	Page:43—46
3. Sulodexide in IgA nephropathy.	Page:47—48
4. A case of membranous nephropathy as a manifestation of graft-versus-host disease.	Page:39—42
5. Association of acute tubular necrosis with gross hematuria in cirrhosis-related immunoglobulin A nephropathy.	Page:43—46
6. Correlation between peripheral venous and arterial blood gas measurements in patients admitted to the intensive care unit: A single-center study.	Page:32—38
7. A case of membranous nephropathy as a manifestation of graft-versus-host disease.	Page:39—42
8. Clostridium difficile-associated diarrhea in dialysis patients.	Page:27—31
9. Correlation between peripheral venous and arterial blood gas measurements in patients admitted to the intensive care unit: A single-center study.	Page:32—38
10. Effects of low-dose niacin on dyslipidemia and serum phosphorus in patients with chronic kidney disease.	Page:21—26
11. Clostridium difficile-associated diarrhea in dialysis patients.	Page:27—31
12. Effect of intradialytic change in blood pressure and ultrafiltration volume on the variation in access flow measured by ultrasound dilution.	Page:16—20
13. Effects of low-dose niacin on dyslipidemia and serum phosphorus in patients with chronic kidney disease.	Page:21—26
14. Understanding and exploiting hepcidin as an indicator of anemia due to chronic kidney disease.	Page:11—15
15. Effect of intradialytic change in blood pressure and ultrafiltration volume on the variation in access flow measured by ultrasound dilution.	Page:16—20
16. Transforming growth factor-beta and the glomerular filtration barrier.	Page:3—10
17. Understanding and exploiting hepcidin as an indicator of anemia due to chronic kidney disease.	Page:11—15
18. Niacin in patients with chronic kidney disease: Is it effective and safe?.	Page:1—2
19. Transforming growth factor-beta and the glomerular filtration barrier.	Page:3—10
20. Niacin in patients with chronic kidney disease: Is it effective and safe?.	Page:1—2